Stocks Health care IMDX
NASDAQ · Health careInsight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. brought in $1.7M of revenue over the twelve months to June 30, 2026, down 60.8% from a year earlier. It posted a net loss of $49.4M. In fiscal 2025 capital spending exceeded operating cash flow by $25.4M. At June 30, 2026 it held $17.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Insight Molecular Diagnostics Inc.
- Net worth
- Insight Molecular Diagnostics Inc. has a market value (market cap) of $81.8M at the latest share price, and shareholders' equity of -$21.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.1M (+115.6% year on year), with a net loss of $50.2M. Over the 12 months to June 30, 2026: revenue $1.7M, net loss $49.4M.
- Cash flow
- In fiscal 2025 operations used $22.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Insight Molecular Diagnostics Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Insight Molecular Diagnostics Inc. does
Insight Molecular Diagnostics Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker IMDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.1M | -$50.2M | -$1.65 | -$25.4M |
| 2024 | $1.9M | -$60.7M | -$4.66 | -$21.2M |
| 2023 | $1.5M | -$27.8M | -$3.75 | -$23.6M |
| 2022 | $958K | -$72.9M | -$13.25 | -$49.9M |
| 2021 | $2.2M | -$64.1M | -$0.72 | -$38.2M |
| 2020 | $1.2M | -$29.9M | -$0.46 | -$27.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IMDX ranks in Health care
Latest SEC filings
What Insight Molecular Diagnostics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026Material agreement8-KInsight Molecular Diagnostics entered into an amendment to modify royalty and sale payout terms related to CNI Monitor.
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 54% to $239K versus the same quarter last year; diluted EPS -$0.31 versus -$0.30.
- August 10, 2026
- July 24, 2026
- June 17, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 99% to $32K versus the same quarter last year; diluted EPS -$0.12 versus -$0.26.
- May 13, 2026
- May 13, 2026Other event 8-K/A
- April 30, 2026
- April 30, 2026Additional proxy material DEFA14A
Insider trades
What the people running Insight Molecular Diagnostics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 1, 2026 | Arno AndrewDirector | Shares withheld for tax | 12,100 | $68.8K |
| July 1, 2026 | Last Andrew J.Director | Shares withheld for tax | 7,700 | $43.8K |
| July 1, 2026 | Silverman LouDirector | Shares withheld for tax | 7,700 | $43.8K |
| June 11, 2026 | Arno AndrewDirector | Received as pay | 32,331 | - |
| June 11, 2026 | Last Andrew J.Director | Received as pay | 26,943 | - |
| June 11, 2026 | Silverman LouDirector | Received as pay | 26,943 | - |
| April 27, 2026 | Broadwood Partners, L.P.10% owner | Bought | 250,923 | $913.1K |
| April 27, 2026 | Broadwood Partners, L.P.10% owner | Boughtindirect | 0 | - |
Who owns IMDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Neal C. Bradsher13D, may seek influence with 2 related filers | 39.7% | April 27, 2026 |
| Patrick W. Smith13G, passive with 1 related filers | 10.5% | December 27, 2024 |
| AWM Investment Company, Inc.13G, passive | 10% | May 9, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 40 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Broadwood Capital Inc | 12,684,884 | +753,045 |
| AWM Investment Company, Inc. | 2,836,692 | +30,436 |
| Vanguard Capital Management LLC | 735,847 | +198,686 |
| Pura Vida Investments, LLC | 484,845 | -462,289 |
| Family Office Research LLC | 368,849 | +241,583 |
| Geode Capital Management, LLC | 256,903 | -5,150 |
| Jane Street Group, LLC | 157,682 | new |
| BlackRock, Inc. | 150,521 | +15,176 |
| Vanguard Fiduciary Trust Co | 124,576 | -8,015 |
| State Street Corp | 92,124 | +41,370 |
| Millennium Management LLC | 82,499 | -20,971 |
| UBS Group AG | 53,276 | +30,525 |
| Northern Trust Corp | 49,090 | 0 |
| Osaic Holdings, Inc. | 39,136 | +15,001 |
| Morgan Stanley | 35,515 | -573 |
| Jefferies Financial Group Inc. | 18,100 | new |
| Marshall Wace, Llp | 16,597 | new |
| ExodusPoint Capital Management, LP | 14,029 | new |
| Axq Capital, LP | 13,407 | new |
| Flatrock Wealth Partners LLC | 13,044 | 0 |
Insiders
7 insiders reported holding 25,889,248 shares in total, about $64.7M at the last price.
| Holder | Shares |
|---|---|
| Broadwood Partners, L.P.10% owner | 25,369,76812,684,884 held indirectly |
| James Andrea S.Chief Financial Officer | 206,060 |
| Arno AndrewDirector | 156,785 |
| Last Andrew J.Director | 58,752 |
| Silverman LouDirector | 55,807 |
| Riggs JoshCEO and President, Director | 38,365 |
| Liu James YangVP ACCT, Cntlr, Treasurer, PAO | 3,711 |
Questions about IMDX
What does Insight Molecular Diagnostics Inc. do?
Insight Molecular Diagnostics Inc. is a company in the Health care sector, listed on NASDAQ as IMDX. Its shares trade on NASDAQ under the ticker IMDX.
What is Insight Molecular Diagnostics Inc.'s net worth?
Insight Molecular Diagnostics Inc. has a market value (market cap) of $81.8M at the latest share price, and shareholders' equity of -$21.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Insight Molecular Diagnostics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $49.4M on revenue of $1.7M.
How much revenue does Insight Molecular Diagnostics Inc. make?
Over the twelve months to June 30, 2026 Insight Molecular Diagnostics Inc. reported revenue of $1.7M. That is 60.8% less than a year earlier.
When did Insight Molecular Diagnostics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 21, 2026.
When is Insight Molecular Diagnostics Inc.'s next earnings report?
Insight Molecular Diagnostics Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare IMDX with
Follow IMDX
Get an email when Insight Molecular Diagnostics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Insight Molecular Diagnostics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.